Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 26th. The
Mubadala Investment Co Pjsc Acquires 24,526 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) major shareholder Mubadala Investment Co Pjsc bought 24,526 shares of the business's stock in a transaction that occurred on Wednesday, Janu
DekaBank Deutsche Girozentrale Acquires 21,500 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
DekaBank Deutsche Girozentrale lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 55.8% in the 3rd quarter, according to the company in its most recent filing with
Shareholders in Recursion Pharmaceuticals (NASDAQ:RXRX) Have Lost 24%, as Stock Drops 5.3% This Past Week
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders should be happy to see the share price up 14% in the last month. But that is minimal compensation for the share price under-performance ov
Blake Borgeson Sells 8,885 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the business's stock in a transaction that occurred on Tuesday, January 24th. The stock was sol
Recursion Pharmaceuticals Releases Compound Intelligence Tool for Drug Discovery, Cellular Imaging Dataset
11:53 AM EST, 01/26/2023 (MT Newswires) -- Recursion Pharmaceuticals (RXRX) said Thursday it released MolRec, a compound intelligence tool for drug discovery, along with RXRX3, its largest open-source
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating
09:52 AM EST, 01/23/2023 (MT Newswires) -- SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating Price: 8.49, Change: -0.16, Percent Change: -
SVB Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
Loading...
No Stock Yet